Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes

Diabetes, Obesity and Metabolism

Volumn 21, Issue 11, 2019, Pages 2394-2404

  Lega, Iliana C ^a,b,c   Bronskill, Susan E ^a,c,d   Campitelli, Michael A ^c   Guan, Jun ^c   Stall, Nathan M ^a,b,d   Lam, Kenneth ^a   McCarthy, Lisa M ^a,d,e   Gruneir, Andrea ^a,c,f   Rochon, Paula A ^a,b,c,d  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

cohort study; database research; pharmaco epidemiology; SGLT2 inhibitor; type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

AGE; AGED; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; FUNGAL GENITAL INFECTION; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PROPENSITY SCORE; RETROSPECTIVE STUDY; SEX; URINARY TRACT INFECTION; ADMINISTRATION AND DOSAGE; ADVERSE EVENT; COMPLICATION; GYNECOLOGIC DISEASE; MALE GENITAL SYSTEM DISEASE; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; FEMALE; GENITAL DISEASES, FEMALE; GENITAL DISEASES, MALE; HUMANS; MALE; MYCOSES; RETROSPECTIVE STUDIES; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; URINARY TRACT INFECTIONS;

EID: 85069880264     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13820     Document Type: Article

References (42)

1. Stenlof K, Cefalu WT, Kim KA, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014;30:163-175.
2. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217-2224.
3. Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1:208-219.
4. Weir MR, Januszewicz A, Gilbert RE, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens. 2014;16:875-882.
5. Chilton R, Tikkanen I, Hehnke U, Woerle HJ, Johansen OE. Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab. 2017;19:1620-1624.
6. Bolinder J, Ljunggren O, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16:159-169.
7. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1730-1735.
8. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.
9. Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin cardiovascular assessment study). Circulation. 2018;137(4):323-334.
10. Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N. Cardiovascular outcomes and risks after initiation of a sodium glucose Cotransporter 2 inhibitor: results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose Cotransporter 2 inhibitors in the real world). Circulation. 2018;137:1450-1459.
11. Birkeland KI, Jorgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017;5:709-717.
12. Diabetes Canada Clinical Practice Guidelines Expert Committee, Lipscombe L, et al. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. Can J Diabetes. 2018;(Suppl 1):S88-S103. http://doi.org/10.1016/j.jcjd.2017.10.034.
13. Standards of Medical Care in Diabetes-2017: Summary of revisions. Diabetes Care. 2017;40(suppl 1):S4-S5.
14. Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103:373-381.
15. Zhu YX, Li T, Fan SR, Liu XP, Liang YH, Liu P. Health-related quality of life as measured with the short-form 36 (SF-36) questionnaire in patients with recurrent vulvovaginal candidiasis. Health Qual Life Outcomes. 2016;14:65.
16. Aballea S, Guelfucci F, Wagner J, et al. Subjective health status and health-related quality of life among women with recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA. Health Qual Life Outcomes. 2013;11:169.
17. Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19:348-355.
18. Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017;7:2824.
19. FDA Drug Safety Communication: FDA Warns that SGLT2 Inhibitors for Diabetes May Result in a Serious Condition of Too Much Acid in the Blood. 2015. https://wayback.archive-it.org/7993/20170112031553/http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Accessed November 20, 2017.
20. Puckrin R, Saltiel MP, Reynier P, Azoulay L, Yu OHY, Filion KB. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55:503-514.
21. Ueda P, Svanstrom H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365.
22. Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with SGLT2 inhibitors: a real-world retrospective cohort study. Diabetes Obes Metab. 2019;21(2):434-438.
23. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
24. Canada PHAo. Chapter 1: Diabetes in Canada: Facts and figures from a public health perspective – Burden. https://www.canada.ca/en/public-health/services/chronic-diseases/reports-publications/diabetes/diabetes-canada-facts-figures-a-public-health-perspective/chapter-1.html. Accessed February 2, 2018.
25. Rochon PA, Gurwitz JH. The prescribing cascade revisited. Lancet. 2017;389:1778-1780.
26. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet. 2007;369:750-756.
27. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002;25:512-516.
28. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario drug benefit database. Can J Clin Pharmacol. 2003;10:67-71.
29. Lipscombe LL, Booth G, Butalia S, et al. Diabetes Canada 2018 clinical practice guidelines for the prevention and Management of Diabetes in Canada: pharmacologic Glycemic Management of Type 2 diabetes in adults. Can J Diabetes. 2018;42:S88-S103.
30. Fadini GP, Bonora BM, Mayur S, Rigato M, Avogaro A. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2018;20:740-744.
31. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33-59.
32. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46:399-424.
33. Nichols GA, Brodovicz KG, Kimes TM, Deruaz-Luyet A, Bartels DB. Prevalence and incidence of urinary tract and genital infections among patients with and without type 2 diabetes. J Diabetes Complications. 2017;31:1587-1591.
34. Burke KR, Schumacher CA, Harpe SE. SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature. Pharmacotherapy. 2017;37:187-194.
35. Chang HY, Singh S, Mansour O, Baksh S, Alexander GC. Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes. JAMA Intern Med. 2018;178:1190-1198.
36. Perlman A, Heyman SN, Matok I, Stokar J, Muszkat M, Szalat A. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report system database. Nutr Metab Cardiovasc Dis. 2017;27:1108-1113.
37. Suzuki M, Hiramatsu M, Fukazawa M, et al. Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans. Diabetes Obes Metab. 2014;16:622-627.
38. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262-274.
39. Administration USFD. 2018. https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm618908.htm. Accessed August 31, 2018.
40. Kumar S, Costello AJ, Colman PG. Fournier's gangrene in a man on empagliflozin for treatment of type 2 diabetes. Diabet Med. 2017;34:1646-1648.
41. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:473-478.
42. Rassen JA, Glynn RJ, Rothman KJ, Setoguchi S, Schneeweiss S. Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. Pharmacoepidemiol Drug Saf. 2012;21:697-709.